{
    "root": "f5305d0f-4cbb-4e42-baef-01ed0f71915c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Duloxetine",
        "suffix": {
            "text": "Delayed-Release"
        }
    },
    "value": "20250328",
    "ingredients": [
        {
            "name": "DULOXETINE HYDROCHLORIDE",
            "code": "9044SC542W"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A",
            "code": "NX76LV5T8J"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "duloxetine delayed-release capsules indicated treatment : major depressive disorder adults generalized anxiety disorder adults pediatric patients 7 years age older diabetic peripheral neuropathic pain adults fibromyalgia adults pediatric patients 13 years age older chronic musculoskeletal pain adults",
    "contraindications": "take duloxetine delayed-release capsules daily , without food . swallow whole ; crush , chew , open capsule ( 2.1 ) indication starting dose target dose maximum dose mdd ( 2.2 ) 40 mg/day 60 mg/day acute treatment : 40 mg/day ( 20 mg twice daily ) 60 mg/day ( daily 30 mg twice daily ) ; maintenance treatment : 60 mg/day 120 mg/day gad ( 2.3 ) adults 60 mg/day 60 mg/day ( daily ) 120 mg/day geriatric 30 mg/day 60 mg/day ( daily ) 120 mg/day pediatrics ( 7 17 years age ) 30 mg/day 30 60 mg/day ( daily ) 120 mg/day dpnp ( 2.4 ) 60 mg/day 60 mg/day ( daily ) 60 mg/day fm ( 2.5 ) adults pediatrics ( 13 17 years age ) 30 mg/day 60 mg/day ( daily ) 60 mg/day chronic musculoskeletal pain ( 2.6 ) 30 mg/day 60 mg/day ( daily ) 60 mg/day discontinuing duloxetine delayed-release capsules : gradually reduce avoid discontinuation symptoms ( 2.8 , 5.7 )",
    "warningsAndPrecautions": "16.1 supplied duloxetine delayed-release capsules , usp features strenght 40 mg body color opaque orange cap color opaque blue cap imprint b body imprint 750 16.2 storage handling store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15-30\u00b0c ( 59-86\u00b0f ) [ usp controlled room temperature ] . repackaged/relabeled : bryant ranch prepack , inc. burbank , ca 91504",
    "adverseReactions": "maois intended treat psychiatric disorders duloxetine delayed-release capsules within 5 days stopping treatment duloxetine delayed-release capsules contraindicated increased risk serotonin syndrome . duloxetine delayed-release capsules within 14 days stopping maoi intended treat psychiatric disorders contraindicated [ ( 2.8 ) ( 5.4 ) ] . starting duloxetine delayed-release capsules patient treated maois linezolid intravenous methylene blue also contraindicated increased risk serotonin syndrome [ ( 2.9 ) ( 5.4 ) ] .",
    "indications_original": "Duloxetine delayed-release capsules is indicated for the treatment of:\n                  \n                     Major depressive disorder in adults\n                     Generalized anxiety disorder in adults and pediatric patients 7 years of age and older\n                     Diabetic peripheral neuropathic pain in adults\n                     Fibromyalgia in adults and pediatric patients 13 years of age and older\n                     Chronic musculoskeletal pain in adults",
    "contraindications_original": "Take Duloxetine delayed-release capsules once daily, with or without food. Swallow whole; do not crush, chew, or open capsule ( 2.1 ) Indication Starting Dose Target Dose Maximum Dose MDD ( 2.2 ) 40 mg/day to 60 mg/day Acute Treatment: 40 mg/day (20 mg twice daily) to 60 mg/day (once daily or as 30 mg twice daily); Maintenance Treatment: 60 mg/day 120 mg/day GAD ( 2.3 ) Adults 60 mg/day 60 mg/day (once daily) 120 mg/day Geriatric 30 mg/day 60 mg/day (once daily) 120 mg/day Pediatrics (7 to 17 years of age) 30 mg/day 30 to 60 mg/day (once daily) 120 mg/day DPNP ( 2.4 ) 60 mg/day 60 mg/day (once daily) 60 mg/day FM ( 2.5 ) Adults and Pediatrics (13 to 17 years of age) 30 mg/day 60 mg/day (once daily) 60 mg/day Chronic Musculoskeletal Pain ( 2.6 ) 30 mg/day 60 mg/day (once daily) 60 mg/day Discontinuing Duloxetine delayed-release capsules: Gradually reduce dosage to avoid discontinuation symptoms ( 2.8 , 5.7 )",
    "warningsAndPrecautions_original": "16.1 How Supplied\n                  Duloxetine delayed-release capsules, USP\n                  \n                     \n                        \n                           \u00a0Features\n                           \u00a0Strenght\n                        \n                        \n                           \n                           \u00a040 MG\n                        \n                        \n                           \u00a0Body Color\n                           \u00a0Opaque orange\n                        \n                        \n                           \u00a0Cap color\n                           \u00a0Opaque blue\n                        \n                        \n                           \u00a0Cap imprint\n                           \u00a0B\n                        \n                        \n                           \u00a0Body imprint\n                           \u00a0750\n                        \n                     \n                  \n                  16.2 Storage and Handling\n                  Store at 25\u00b0C (77\u00b0F); excursions permitted to 15-30\u00b0C (59-86\u00b0F) [see USP Controlled Room Temperature].\n                  Repackaged/Relabeled by:\n                  Bryant Ranch Prepack, Inc.\n                  Burbank, CA 91504",
    "adverseReactions_original": "The use of MAOIs intended to treat psychiatric disorders with Duloxetine delayed-release capsules or within 5 days of stopping treatment with Duloxetine delayed-release capsules is contraindicated because of an increased risk of serotonin syndrome. The use of Duloxetine delayed-release capsules within 14 days of stopping an MAOI intended to treat psychiatric disorders is contraindicated [see Dosage and Administration (2.8) and Warnings and Precautions (5.4)].\n                  \n                  Starting Duloxetine delayed-release capsules in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see Dosage and Administration (2.9) and Warnings and Precautions (5.4)]."
}